Samsung Biologics Shares Slide on $280M GSK Plant Acquisition
Samsung Biologics’ stock dropped nearly 5% after announcing the acquisition of GSK’s Maryland-based drug manufacturing facility for $280 million. The Rockville site adds 60,000 liters of cGMP-certified capacity, offering a faster market entry than building new infrastructure.
Investors reacted cautiously to the deal’s near-term costs, overshadowing its strategic fit with Samsung’s global expansion ambitions. The company plans additional investments to modernize the facility with automation and digital manufacturing systems, targeting completion by Q1 2026 pending regulatory approvals.
The MOVE highlights the growing pressure on CDMOs to secure Western production assets amid shifting pharma supply chains. Samsung’s willingness to absorb upfront costs reflects long-term confidence in biologics demand, though execution risks remain.
